Along with our partners at @Merck, we announced positive results from the Phase 3 INTerpath-001 study of intismeran autogene, our investigational individualized neoantigen therapy, in combination with pembrolizumab as adjuvant treatment in patients with completely resected Stage IIB-IV melanoma. This marks the first and only combination regimen to demonstrate a clinically meaningful improvement over pembrolizumab alone, a current standard-of-care for these patients.

In our latest IR Insights, members of our executive team sat down to reflect on what this means: https://www.modernatx.com/ir-insights-phase-3-intesmeran